Perakizumab
Perakizumab
Perakizumab (pronunciation: peh-rah-kee-zoo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biologic therapy that targets and neutralizes specific proteins in the body that contribute to the disease process.
Etymology
The name "Perakizumab" is derived from the standard nomenclature for therapeutic monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-kizu-" suggests its humanized nature. The prefix "Pera-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Perakizumab works by binding to a specific protein in the body that is involved in the inflammatory process. By neutralizing this protein, it can help to reduce inflammation and alleviate symptoms of the disease.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biologic therapy: Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases.
See Also
External links
- Medical encyclopedia article on Perakizumab
- Wikipedia's article - Perakizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski